CD274 and neoplasm: Interestingly, the injection of anti-PD-L1 antibodies at an early stage of tumor growth (Day 8) showed high therapeutic activity regardless of the timing of Am80 administration, indicating that MB49 tumors become increasingly resistant to anti-PD-L1 therapy over time (Supplementary Fig. S4A, B, Groups c and d).